未登录.png)
分享.png)
收藏Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer曲妥珠单抗Deruxtecan在早期乳腺癌残留HER2-Positive中的应用
Loibl, Sibylle; Park, Yeon Hee; Shao, Zhiming; Huang, Chiun-Sheng; Barrios, Carlos; Abraham, Jame; Prat, Aleix; Niikura, Naoki; Im, Seock-Ah; Li, Wei; Li, Huiping; Wang, Yongsheng; Yao, Herui; Kim, Sung-Bae; Geng, Cui-zhi; Rodriguez Pantigoso, Wuilbert; Ramirez Godinez, Francisco Javier; Song, Chuangui; Ching Chang, Yuan; Antoniazzi, Augusto; Chen, Shin-Cheh; Li, Zhigao; Nowecki, Zbigniew; Lim, Joline; Mathias, Elton; Sato, Yuta; Lu, Wenjing; Abdel-Monem, Hanan; Untch, Michael; Geyer, Charles E. 分享 收藏 分享 收藏 分享 收藏 Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancerDalpiciclib 联合芳香化酶抑制剂与术前化疗治疗ER阳性、HER2阴性乳腺癌Wang, Haoqi; Zhang, Guoyu; Gao, Wei; Li, Sainan; Yang, Shan; Zhang, Xi; Wang, Jiaxing; Li, Chunxiao; Gao, Shan; Geng, Cuizhi 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2-stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory studyZhang, Lina; Liu, Yueping; Yang, Chao; Ma, Jie; Li, Yuntao; Luo, Ruizhen; Han, Jianjun; Wang, Xiaochun; Zhang, Zhisheng; Ma, Li; Cai, Haifeng; Kong, Xiangshun; Wang, Zunyi; Zhou, Xinping; Shi, Jiajie; Zhang, Yanshou; Wang, Meiqi; Wang, Jiaxing; Geng, Cuizhi 分享 收藏 An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axisYang, Xiaolu; Li, Yilun; Peng, Yaqi; Chang, Yuan; He, Binglu; Zhang, Tianqi; Zhang, Shiyu; Geng, Cuizhi; Liu, Yunjiang; Li, Xiaolong; Hao, Jun; Ma, Li 分享 收藏 A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancerJiang, Zefei; Ouyang, Quchang; Sun, Tao; Zhang, Qingyuan; Teng, Yuee; Cui, Jiuwei; Wang, Haibo; Yin, Yongmei; Wang, Xiaojia; Zhou, Xin; Wang, Yongsheng; Sun, Gang; Wang, Jingfen; Zhang, Lili; Yang, Jin; Qian, Jun; Yan, Min; Liu, Xinlan; Yi, Tienan; Cheng, Ying; Li, Man; Zang, Aimin; Wang, Shusen; Wang, Chuan; Wu, Xinhong; Cheng, Jing; Li, Hui; Lin, Ying; Geng, Cuizhi; Gu, Kangsheng; Xie, Chunwei; Xiong, Huihua; Wu, Xiaohong; Yang, Junlan; Li, Qingshan; Chen, Yiding; Li, Fanfan; Zhang, Anqin; Zhang, Yongqiang; Wu, Yudong; Nie, Jianyun; Liu, Qiang; Wang, Kun; Mo, Xueli; Chen, Lilin; Pan, Yueyin; Fu, Peifen; Zhang, Helong; Pang, Danmei; Sheng, Yuan; Han, Yunwei; Wang, Hongxia; Cang, Shundong; Luo, Xianming; Yu, Wenbo; Deng, Rong; Yang, Chaoqiang; Keegan, Patricia 分享 收藏 A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancerZhang, Qingyuan; Wang, Zhonghua; Yao, Wei; Wang, Shufang; Zhang, Gaochong; Chen, Jianmin; Hou, Qingsong; Li, Simon; Li, Hongsheng; Ye, Changsheng; Sun, Tao; Yang, Hongjian; Chen, Zhendong; Wang, Zhihong; Liu, Xiaoan; Geng, Cuizhi; Li, Xingrui; Zhang, Jin; Zheng, Hong; Shao, Zhimin 分享 收藏 The study on circRNA profiling uncovers the regulatory function of the hsa_circ_0059665/miR-602 pathway in breast cancerWu, Zhenyu; Wu, Ming; Jiang, Xia; Shang, Fangjian; Li, Sainan; Mi, Yunzhe; Geng, Cuizhi; Tian, Yanfeng; Li, Zhongxin; Zhao, Zengren 分享 收藏 QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trialZuo, Wenjia; Wang, Zhonghua; Qian, Jun; Ma, Xiaopeng; Niu, Zhaofeng; Ou, Jianghua; Mo, Qinguo; Sun, Jing; Li, Xinzheng; Wang, Qitang; Yao, Yongzhong; Yu, Guohua; Li, Hongsheng; Chen, Dedian; Zhang, Hao; Geng, Cuizhi; Qiao, Guangdong; Zhao, Mengmeng; Zhang, Baihui; Kang, Xiaoyan; Zhang, Jin; Shao, Zhimin 分享 收藏 CDK4/6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor- positive, HER2-negative stage II-III breast cancer: a single-arm exploratory trialZhang, Lina; Yang, Chao; Ma, Jie; Li, Yuntao; Luo, Ruizhen; Han, Jianjun; Wang, Xiaochun; Zhang, Zhisheng; Ma, Li; Cai, Haifeng; Kong, Xiangshun; Wang, Zunyi; Zhou, Xinping; Liu, Yueping; Shi, JiaJie; Zhang, Yanshou; Wang, Meiqi; Wang, Jiaxing; Geng, Cuizhi 分享 收藏 Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA)Yang, Benlong; Liu, Jian; Wang, Haibo; Chen, Yiding; Geng, Cuizhi; Rao, Nanyan; Han, Siyuan; Zhang, Antai; Shi, Jinping; Zhang, Qiang; Zhao, Wenhe; Wu, Jiong 分享 收藏 分享 收藏 Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 studyYin, Yongmei; Wu, Xinhong; Ouyang, Quchang; Yan, Min; Song, Lihua; Liu, YunPeng; Tong, Zhongsheng; Geng, Cuizhi; Wang, Ying; Yu, Guohua; Wang, Xiang; Cheng, Ying; Zhao, Weihong; Jin, Xiaoping; Diao, Yina; Liu, Gesha; Yang, Mengyu; Yang, Yue; Yang, Yalan; Lu, Lian; Ge, Junyou; Li, Jin; Li, Qun 分享 收藏 Identification of molecular subtypes based on chromatin regulator-related genes and experimental verification of the role of ASCL1 in conferring chemotherapy resistance to breast cancerLi, Yilun; Yang, Xiaolu; Geng, Cuizhi; Liu, Yunjiang; Tang, Tiantian; Zhang, Lina; Liu, Fei; Zhang, Meng; Hao, Jun; Ma, Li 分享 收藏 Effective anti-diarrhea strategies for pyrotinib (PYR) plus trastuzumab (H) and docetaxel (T) in patients ( pts) with HER2+metastatic breast cancer (mBC): a multicenter, phase 1 trial (PHAENNA)Yao, H.; Shi, Y.; Yao, Y.; Li, H.; Zhou, H.; Wang, S.; Qin, Q.; Li, W.; Geng, C.; Wang, M.; Wang, X.; Cao, Y.; Yu, Z.; Du, C.; Zhao, W.; Wu, S.; Cui, Y.; Liu, P.; Lin, J.; Song, E. 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
OAAI